Of the 361 patients with esophageal adenocarcinoma, 187 (52%) were tested for PD-L1, 194 (54%) were tested for MMR/MSI, and 302 (84%) were tested for HER2. Here, ERBB2 is linked to esophageal adenocarcinoma.